In our ongoing studies we focus on two aspects of cancer immunotherapy.

First, we are developping enhanced tumor antigen-specific vaccines that would prime antigen-specific T cell responses to fight tumor cells.

Second, we aim to generate immunostimulatory approaches that would allow strong activation of the immune system to develop boosted anti-tumoral responses and to enhance the potency of currently approved immunotherapies in hard-to-tackle tumor entitites.

Figure created with FigureLabs schematically illustrating an AAV-based cancer vaccine.